These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
407 related articles for article (PubMed ID: 19638322)
21. Acylated and deacylated saponins of Quillaja saponaria mixture as adjuvants for the FML-vaccine against visceral leishmaniasis. Oliveira-Freitas E; Casas CP; Borja-Cabrera GP; Santos FN; Nico D; Souza LO; Tinoco LW; da Silva BP; Palatnik M; Parente JP; Palatnik-de-Sousa CB Vaccine; 2006 May; 24(18):3909-20. PubMed ID: 16556475 [TBL] [Abstract][Full Text] [Related]
22. Protection of mice against visceral leishmaniasis by immunization with promastigote antigen incorporated in liposomes. Ali N; Afrin F J Parasitol; 1997 Feb; 83(1):70-5. PubMed ID: 9057699 [TBL] [Abstract][Full Text] [Related]
23. Non PC liposome entrapped promastigote antigens elicit parasite specific CD8+ and CD4+ T-cell immune response and protect hamsters against visceral leishmaniasis. Sharma SK; Dube A; Nadeem A; Khan S; Saleem I; Garg R; Mohammad O Vaccine; 2006 Mar; 24(11):1800-10. PubMed ID: 16310900 [TBL] [Abstract][Full Text] [Related]
24. Effect of immunization with lipid associated polysaccharide antigen and anti CD-2 antibodies on class II MHC expression and cellular immune response in BALB/C mice infected with Leishmania donovani. Bimal S; Bagchi AK; Das V; Sinha PK; Lal CS; Ranjan A; Gupta AK; Kar SK Indian J Exp Biol; 2001 Sep; 39(9):878-82. PubMed ID: 11831368 [TBL] [Abstract][Full Text] [Related]
25. Leishmania donovani serine protease encapsulated in liposome elicits protective immunity in experimental visceral leishmaniasis. Das P; Paik D; Naskar K; Chakraborti T Microbes Infect; 2018 Jan; 20(1):37-47. PubMed ID: 28970116 [TBL] [Abstract][Full Text] [Related]
26. Immunization with the cysteine proteinase Ldccys1 gene from Leishmania (Leishmania) chagasi and the recombinant Ldccys1 protein elicits protective immune responses in a murine model of visceral leishmaniasis. Ferreira JH; Gentil LG; Dias SS; Fedeli CE; Katz S; Barbiéri CL Vaccine; 2008 Jan; 26(5):677-85. PubMed ID: 18160187 [TBL] [Abstract][Full Text] [Related]
27. Leishmania donovani recombinant iron superoxide dismutase B1 protein in the presence of TLR-based adjuvants induces partial protection of BALB/c mice against Leishmania major infection. Daifalla NS; Bayih AG; Gedamu L Exp Parasitol; 2012 Jul; 131(3):317-24. PubMed ID: 22580023 [TBL] [Abstract][Full Text] [Related]
28. Vaccination with liposomal leishmanial antigens adjuvanted with monophosphoryl lipid-trehalose dicorynomycolate (MPL-TDM) confers long-term protection against visceral leishmaniasis through a human administrable route. Ravindran R; Maji M; Ali N Mol Pharm; 2012 Jan; 9(1):59-70. PubMed ID: 22133194 [TBL] [Abstract][Full Text] [Related]
29. Serodiagnostic and immunoprophylactic potential of a 78kDa protein of Leishmania donovani of Indian origin. Mukherjee M; Bhattacharyya A; Duttagupta S Med Sci Monit; 2002 Apr; 8(4):BR117-22. PubMed ID: 11951057 [TBL] [Abstract][Full Text] [Related]
30. Immune induction by adjuvanted Leishmania donovani vaccines against the visceral leishmaniasis in BALB/c mice. Goyal DK; Keshav P; Kaur S Immunobiology; 2021 Mar; 226(2):152057. PubMed ID: 33545508 [TBL] [Abstract][Full Text] [Related]
31. Pure protein from Leishmania donovani protects mice against both cutaneous and visceral leishmaniasis. Rachamim N; Jaffe CL J Immunol; 1993 Mar; 150(6):2322-31. PubMed ID: 8450215 [TBL] [Abstract][Full Text] [Related]
32. gp63 in stable cationic liposomes confers sustained vaccine immunity to susceptible BALB/c mice infected with Leishmania donovani. Bhowmick S; Ravindran R; Ali N Infect Immun; 2008 Mar; 76(3):1003-15. PubMed ID: 18195029 [TBL] [Abstract][Full Text] [Related]
33. Isotype profiles of Leishmania donovani-infected BALB/c mice: preferential stimulation of IgG2a/b by liposome-associated promastigote antigens. Afrin F; Ali N J Parasitol; 1998 Aug; 84(4):743-8. PubMed ID: 9714204 [TBL] [Abstract][Full Text] [Related]